{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP-bt88IDA","lastupdate":"2023-09-07T00:00:00.000Z","update_date":"2023-09-07T00:00:00.000Z","lastModified":"May 29, 2024","active":1,"confidence_score":92,"confidence_score_reason":"markets, not claimed","urlname":"isotopia","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$WZgb1ujn9CV6q9Ozlj4Qw1zb6TZ1G5qFv31XixSIvcaRAAnwjMqdYq","name":"Isotopia Molecular Imaging","oneliner":"Radioactive Isotopes for Nuclear Therapy","registrar":"513945717","website":"https://isotopia-global.com/","careerspage":"https://isotopia-global.com/careers","founded_month":2,"founded_year":2007,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/Isotopia_il","youtube":"https://www.youtube.com/channel/UC0AuXqBUI4KHM-Opk8sq7Eg","facebook":"https://www.facebook.com/Isotopia.Molecular.Imaging","linkedin":"https://www.linkedin.com/company/7228777","instagram":""},"social":["https://www.linkedin.com/company/7228777","https://twitter.com/Isotopia_il","https://www.facebook.com/Isotopia.Molecular.Imaging","https://www.youtube.com/channel/UC0AuXqBUI4KHM-Opk8sq7Eg"],"flattenedsociallinks":"https://www.linkedin.com/company/7228777|https://twitter.com/Isotopia_il|https://www.facebook.com/Isotopia.Molecular.Imaging|https://www.youtube.com/channel/UC0AuXqBUI4KHM-Opk8sq7Eg","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":109,"patent":1,"raised":3750000,"stage":"Mature","public_stage":"Mature","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Isotopia",""],"about":"Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes diagnostic and therapeutic radioactive isotopes and advanced PET and SPECT radiotracers.\n\nIts flagship product, the radioisotope Lutetium-177 (both C.A and N.C.A), has attracted considerable attention and exhibited great promise in treating a variety of late-stage cancers, including metastatic prostate cancer and neuroendocrine tumors.\n\nIts production facilities include an advanced nuclear pharmacy that provides radionuclide labelled compounds for PET/SPECT imaging, a cyclotron facility, and an aseptic manufacturing plant that also offers contract manufacturing services (CMO).","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97239130314","country":null,"address":{"israeli":[{"id":"048fafc2-3486-4e04-adb9-3033db9a25ab","city":"Petah Tikva","type":null,"address":"Alexander Yanai Street 39, Petah Tikva, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null},{"id":"r4qk3Up8KUI4Mfjo7NX5DLNu1czDc4LFAAKNSugSz0x09lCnqIAQ4q","city":"Yavne","type":null,"address":"Yavne, Israel","placeid":"ChIJs32SQXq6AhUR5H65MScHmUE","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":[{"id":"Db5tH2o2Tuia7C0ZnpQhaOIzkLDwP3TUsHQbsDIgaUVaNHsYpkLeXB","city":"Westfield","address":"17075 Oak Ridge Rd, Westfield, IN 46074, USA","country":"United States","placeid":"ChIJA01VZ-OuFIgRclY8ifAh2_g"}]},"headquarter_address":null,"district":"Center District","news":[{"id":"IhrdHDvFKNIZIkLNMTHk83h1pWnmfrbWDUKCUH3XCkYUo1n0ZR60Kc","date":"May 30, 2025","link":"https://www.prnewswire.com/il/news-releases/isotopia-and-cardirad-announce-launch-of-isoprotrace-in-sweden-and-denmark-expanding-access-to-advanced-prostate-cancer-imaging-302468339.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"product launch","round":null,"company":"Isotopia Molecular Imaging","layoffs":null,"summary":"Isotopia Molecular Imaging, in collaboration with Cardirad, has launched Isoprotrace®, a Gallium-68 Gozetotide preparation kit for prostate cancer imaging, in Sweden and Denmark. This product is designed to enhance the detection and management of prostate cancer through PET imaging. The launch signifies a significant expansion into the Nordic markets, providing healthcare professionals with advanced diagnostic tools. Cardirad will distribute Isoprotrace® across Sweden and Denmark, ensuring accessibility to medical facilities. The product has already received marketing authorization in the Netherlands, UK, and Germany, with plans for further expansion in the EU. This launch underscores Isotopias commitment to advancing prostate cancer care globally.","partners":"Cardirad","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["prostate cancer","diagnostic tools","Nordic markets","radiopharmaceuticals","healthcare"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lJ6AKBbkq9NGA9u2VYnJbKPMyHipPe6q7eLbe7pSocMhFoqjQ5brj9","news_summary":"/PRNewswire/ -- Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sFGwiFVjyjKwv1p1bslCjxLnGZXwGfwammJqqvXwHCWwIEH7758AB4","date":"Mar 10, 2025","link":"https://www.prnewswire.com/il/news-releases/isotopia-announces-official-commercial-launch-of-isoprotrace-in-germany-in-partnership-with-dsd-pharma-302396757.html","source":"www.prnewswire.com","visible":1,"analysis":{"date":"Wed Mar 12 2025","status":-1,"message":"","entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"KIac1wykkUqparZD4qZnVlwYaSHRyYmlY4Icy2EUvbmoKPQQnDHrk0","news_summary":"/PRNewswire/ -- Isotopia, a leading developer of innovative radio-pharmaceuticals, has officially launched Isoprotrace® in Germany. DSD Pharma, a trusted...","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"EvoPvMjbfUyGat6ZYfEHcp1T7iyZQ5T8GbjyAlKZTfYRKam0lL7GKO","date":"Jan 30, 2025","link":"https://www.prnewswire.com/il/news-releases/kinectrics-and-isotopia-enter-agreement-for-supply-of-gadolinium-160-gd-160-to-support-production-of-terbium-161-tb-161-for-advanced-radiotherapeutics-302363519.html","source":"www.prnewswire.com","visible":1,"analysis":{"date":"Tue Feb 18 2025","status":-1,"message":"EPIPE","entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"41lylShewHSkMJVCfouLbL2uCwVQAZWYOC5whFpCEVHMAmYsVzzziJ","news_summary":"/PRNewswire/ -- Kinectrics and Isotopia have announced a groundbreaking agreement under which Kinectrics will provide Isotopia with a reliable supply of...","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"WDdSuPJxlaB9lFYOdITLVvtcEP5KSvbYd3fIFlGk6hU9sPfEvTHOhA","date":"Sep 6, 2023","link":"https://www.prnewswire.co.uk/news-releases/isotopia-issues-a-call-to-action-to-the-radionuclide-therapy-industry-301919212.html","source":"www.prnewswire.co.uk","visible":1,"analysis":{"tags":"Collaboration, Supply Chain","company":"Isotopia Molecular Imaging","layoffs":"Not Mentioned","summary":"Isotopia Molecular Imaging, a global pharmaceutical company, is calling for urgent collaboration in the Lu-177 radiopharmaceuticals sector. The companys CEO, Dr. Eli Shalom, highlighted the current monopoly of Yb-176 production and the insufficient supply to meet growing demand. He also pointed out the close ties between research reactors and certain pharmaceutical firms, which restrict broader collaborations with various Lu-177 producers. Dr. Shalom emphasized the need for collaboration to ensure the sectors success and bolster investor confidence.","partners":"Not Mentioned","customers":"Not Mentioned","investors":"Not Mentioned","confidence":9,"key_topics":"Lu-177 Radiopharmaceuticals, Supply Chain, Collaboration, Market Imbalance, Investor Confidence","date_of_event":"Sept. 6, 2023","valuation_amount":"Not Mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not Mentioned","structured_issues":"Partners","acquisition_amount":"Not Mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"pnJyHcPWbwnRpjvd1rGjkAccKRgg6YpLfncogqyetMBHqrC8ihGhO0","news_summary":"Isotopia Issues a call to action to the radionuclide Therapy industry.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"idp081MSjyej0UO24kOVFxTlS7v6Cu7iSq2gyPdpx23Mu76qakPAPo","date":"Sep 21, 2022","link":"https://www.businesswire.com/news/home/20220921005038/en/Clovis-Oncology-and-Isotopia-Announce-Lutetium-177-Clinical-Supply-Agreement","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"egjxT96HBAxoHHKwFWAWsJgmojbR1XiFQQb6gUbxT0ND7jo1iSZNUQ","news_summary":"Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"379e94f8-61e9-4951-9b3c-9d4c47e94ee6","date":"Jun 9, 2022","link":"https://www.prnewswire.com/il/news-releases/isotopia-and-cpdc-successfully-deliver-first-doses-of-nca-lu-177-to-north-american-customers-301564976.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"production, supply, radiometal, radiotherapy, manufacturing","company":"Centre for Probe Development and Commercialization (CPDC)","layoffs":null,"summary":"Isotopia Molecular Imaging has successfully transferred its technology for the production of n.c.a. Lu-177 to CPDCs GMP facility. CPDC has shipped its first doses of commercial n.c.a. Lu-177, which is a commonly used radiometal for targeted radiotherapy. This collaboration strengthens Isotopias global footprint in the n.c.a. Lu-177 supply chain and ensures a reliable supply of medical isotopes. CPDC, a leading CDMO, aims to become an all-encompassing radiopharmaceutical CDMO. Isotopia plans to create a global footprint for efficient production of Lu-177, with manufacturing sites in Israel, North America, and Europe. The article invites readers to learn more about this milestone at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 annual meeting.","partners":"Isotopia","customers":null,"investors":null,"confidence":8,"key_topics":["Isotopia","n.c.a. Lu-177","CPDC","radiopharmaceuticals","global supply"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NCDICmiVgopLu8nEFxQOtQuRk5eHOdJAfBM7aFwSpJzkDFOHEfRj1Z","news_summary":"Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"XhGyWfT0s1B1QLpNtuskeMMKv2kYy3I9O2h2eJLrTS2Sx1hTgKWsCC","date":"Nov 9, 2021","link":"https://www.prnewswire.com/news-releases/isotopia-and-the-peter-maccallum-cancer-centre-announce-terbium-161-clinical-study-collaboration-301420069.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical research, supply agreement, therapeutic isotope, targeted cancer treatment","company":"Isotopia Molecular Imaging Limited","layoffs":null,"summary":"Isotopia Molecular Imaging Limited has signed a clinical research and supply agreement with Peter MacCallum Cancer Centre for the medical radioisotope no-carrier-added Terbium-161 (n.c.a. Tb-161), an innovative therapeutic isotope used for targeted cancer treatment. The agreement will support a first-in-human pilot study conducted by the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at Peter Mac. The study will use 161Tb, a radioactive compound, linked to a small molecule targeting prostate specific membrane antigen (PSMA) to treat men with advanced prostate cancer. Isotopia aims to develop a new generation of therapeutic isotopes for targeted therapy.","partners":["Peter MacCallum Cancer Centre"],"customers":null,"investors":null,"confidence":8,"key_topics":["Theranostics","radioactive molecules","prostate cancer","clinical trial","targeted therapy"],"date_of_event":"November 9, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yf68a1dTuHKORlfAugNMmQoLgfvpLIgR1iOSJNGD5lwQVduiH8Uqzl","news_summary":"Isotopia and the Peter MacCallum Cancer Centre announce Terbium-161 clinical study collaboration","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"884f6c13-48b8-4f23-a1de-460ddb8ba408","date":"Nov 5, 2020","link":"https://www.prnewswire.com/il/news-releases/isotopia-molecular-imaging-begins-clinical-supply-collaboration-with-y-mabs-therapeutics-inc-301167342.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"collaboration, medical radioisotope, clinical development, cancer treatment","company":"Isotopia Molecular Imaging","layoffs":null,"summary":"Isotopia Molecular Imaging has announced a collaboration with Y-mAbs Therapeutics for the supply of the medical radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu) to support clinical development for 177Lu-DTPA-omburtamab for the treatment of B7-H3 positive Central Nervous System and Leptomeningeal Metastasis from tumors in adult patients. Isotopia has developed a unique method to produce a highly pure form of Lu-177. The collaboration aims to improve the quality of life of cancer patients with targeted radionuclide therapies.","partners":["Y-mAbs Therapeutics"],"customers":null,"investors":null,"confidence":9,"key_topics":["Isotopia Molecular Imaging","Y-mAbs Therapeutics","177Lu-DTPA-omburtamab","Lutetium-177","Targeted Radionuclide Therapy"],"date_of_event":"2020-11-05","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"d4KUD63UW5YiyZcNUOnIOb1yFB6PEupKwPsupvmJyLzjnIBjaIsQ85","news_summary":"Isotopia Molecular Imaging begins clinical supply collaboration with Y-mAbs Therapeutics, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c19009c6-d4af-4407-87f4-3445d812113c","date":"Sep 9, 2020","link":"https://www.prnewswire.com/il/news-releases/isotopia-molecular-imaging-and-cpdc-announce-production-agreement-for-nca-lu-177-301125481.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"production and distribution agreement","company":"Isotopia Molecular Imaging","layoffs":null,"summary":"Isotopia Molecular Imaging and CPDC have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for cancer treatment. CPDC will produce n.c.a. Lu-177 in collaboration with Isotopia for distribution in North America. Isotopias CEO stated that the partnership will enhance distribution and secure supply for their clients in North America. Isotopia and CPDC also plan to expand their partnership for commercial-scale production. The Centre for Probe Development and Commercialization (CPDC) is a global leader in radiopharmaceutical development and manufacturing. NuGeneris Specialty Pharmaceuticals Inc., a subsidiary of CPDC, will be involved in the production. The partnership aims to ensure a stable and reliable supply of medical isotopes for life-altering therapies.","partners":"CPDC","customers":null,"investors":null,"confidence":9,"key_topics":["Lutetium-177","radiopharmaceuticals","Targeted Radionuclide Therapy","CPDC","NuGeneris Specialty Pharmaceuticals Inc."],"date_of_event":"September 8, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bWWNT1VpQqPO5pgpSV0mMPDVNmEJnKnK24KbpdhYHecPYpJDzM9Wt1","news_summary":"Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"51951df5-9df7-4d63-8f6f-2864001062b4","date":"Feb 13, 2020","link":"https://www.prnewswire.com/news-releases/isotopia-molecular-imaging-and-eckert--ziegler-to-start-partnership-for-prostate-cancer-imaging-301004306.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Prostate Cancer Imaging","company":"Isotopia Molecular Imaging","layoffs":"N/A","summary":"Isotopia Molecular Imaging has entered into a development partnership with Eckert & Ziegler for the development of its PSMA-11-Kit for prostate cancer imaging. The agreement includes the collaboration to make operation of the Kit feasible on E&Z´s KitLab, having E&Z´s GalliaPharm® (68Ge/68Ga generator) in the Drug Master File (DMF) of the Kit, and completion of the necessary steps to obtain marketing authorization in the EU.","partners":"Eckert & Ziegler","customers":"N/A","investors":"N/A","confidence":10,"key_topics":["Development Partnership","Prostate Cancer Imaging","Eckert & Ziegler","PSMA-11-Kit","Marketing Authorization"],"date_of_event":"Feb. 13, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lZAqRTb7AV9iXTqDw6sXjslm1r5XXK9L3KO57Dc1VyBZAzCLUdRP6M","news_summary":"Isotopia Molecular Imaging and Eckert & Ziegler to Start Partnership for Prostate Cancer Imaging","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"896e6a08-c038-401f-bee5-20c26834b629","date":"Jul 10, 2018","link":"https://www.eurekalert.org/pub_releases/2018-07/bu-ica071018.php","source":"www.eurekalert.org","visible":1,"analysis":{"tags":"Cancer Research, Theranostics","company":"Isotopia","layoffs":"Not mentioned","summary":"Israeli company Isotopia is partnering with Prof. Rachela Popovtzer of Bar-Ilan University to develop a radioactive marker for cancer detection. The marker, based on nanoparticles, aims to distinguish between tumors and inflammation, addressing a common issue with current imaging methods. The research is part of the Magneton program, funded by the Innovation Authority, which encourages the transfer of academic technological knowledge to innovative industry products. Isotopias CEO, Dr. Eli Shalom, highlighted the potential of the technology to improve diagnoses and its compatibility with existing PET/CT centers.","partners":"Prof. Rachela Popovtzer of Bar-Ilan University, Innovation Authority, Birad Research and Development Company Ltd.","customers":"Not mentioned","investors":"Innovation Authority","confidence":9,"key_topics":["Cancer Detection","Nanoparticles","PET Scan","Theranostics","Research Collaboration"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6nDTfhWC4Sfm83bLqzStHMShWnFUY3K6F8UO5CWS4yNzTWvXpwiHXE","news_summary":"Isotopia Co. and Bar-Ilan U. developing new method for diagnosis and treatment of cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"17e1309a-7c34-40ed-9d5a-701bfd1007c2","date":"Jul 29, 2007","link":"https://en.globes.co.il/en/article-1000237051","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"Isotopia Molecular Imaging Ltd","layoffs":null,"summary":"Metro Ontario will invest NIS 13 million in Isotopia Molecular Imaging Ltd, a company that makes substances for use in PET scans and conducts nuclear medical research. The investment is expected to have a positive impact on the growth of the company.","partners":null,"customers":null,"investors":"Metro Ontario","confidence":8,"key_topics":["Isotopia Molecular Imaging","PET scans","nuclear medical research","substances","oncology and cardiology centers"],"date_of_event":"July 29, 2007","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"NIS 13 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fbyCBV1soVMqxUUUM2eJKnDcq8HiLfOMOgiQ9HiUHiLf8zeoh3eu36","news_summary":"Metro Ontario to invest in Isotopia Molecular Imaging","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":12,"techcommunityinvolvement":null,"mediagallery":[{"id":"zhpYP82pmEgDYQ6lAZ3fzlSnhkwbJteC5I0ntM0i2jRmhKL58BAJ84","timestamp":"2023-10-05 08:11:04.000000","resources_type":1,"resources_title":"","resources_file_name":"$tVzahrZpnAUFwcCw9ZaWLqjWy1rKSGrLsTEy3HHnnHC0GmQGkxOMhZ.jpeg","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$tVzahrZpnAUFwcCw9ZaWLqjWy1rKSGrLsTEy3HHnnHC0GmQGkxOMhZ.jpeg","url":"https://storage.googleapis.com/clean-finder-353810/$tVzahrZpnAUFwcCw9ZaWLqjWy1rKSGrLsTEy3HHnnHC0GmQGkxOMhZ.jpeg"},{"id":"tTx5yQUxJqAalpFK3NSu3f0cgvS8tOnVefk7doedgG5IjHf6bLDPy0","timestamp":"2022-10-26 13:20:17.000000","resources_type":2,"resources_title":"","resources_file_name":"GJkFCh0kNSI","alt":"","imageurl":"https://img.youtube.com/vi/GJkFCh0kNSI/0.jpg","url":"http://youtu.be/GJkFCh0kNSI"},{"id":"n9cRUXWdE3P5t5GK3RwsYU8UBWIS8NOxU93tPu6eOyke014QlYpA0D","timestamp":"2022-10-26 13:19:53.000000","resources_type":2,"resources_title":"","resources_file_name":"2wFKKpLC3qM","alt":"","imageurl":"https://img.youtube.com/vi/2wFKKpLC3qM/0.jpg","url":"http://youtu.be/2wFKKpLC3qM"},{"id":"e9rwjkPyFhd5dJsvE6q3hNXYeHWvb1u8XwLMXj2zpxpRtodfUa1H6A","timestamp":"2022-10-26 13:19:24.000000","resources_type":2,"resources_title":"","resources_file_name":"gyQRKhzO48A","alt":"","imageurl":"https://img.youtube.com/vi/gyQRKhzO48A/0.jpg","url":"http://youtu.be/gyQRKhzO48A"}],"tags":["precision-medicine","cancer-therapy","cancer","targeted-cancer-therapy","radiology","scanning","radiopharmaceuticals","hospitals","pharma-companies","doctors","healthcare-providers","cancer-diagnostics","cancer-research","pharmaceuticals","clinical-trials","bioconvergence"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Juzz-kKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["PSMA","Lu-177","Isoprotrace","psma labelling kit","Lutetium 177"],"geomarkets":["Central America","Asia","South America","Israel","Africa","North America","Europe"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"$3.75M","totalrounds":1,"fundingstage":"Mature","totalfunding":"$3.75M","publicinvestors":1,"lastpublicfunding":3750000,"totalpublicrounds":1,"totalpublicfunding":3750000},"team":[{"name":"Eli Shalom, Dr.","email":"eshalom@isotopia.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwMCRjYQLDA","bounced":false,"claimed":0,"founder":1,"urlname":"eli-shalom-dr","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAwJyYiwoM","position":"Co-founder & CEO","last_name":"Shalom, Dr.","claimtoken":"KLy3O7rUOPbd3Q5p3uEwvq6gKgi7m3Dfb2r6Po1OepU2QZctxxw6WD","first_name":"Eli","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dr-eli-shalom-69274216/","unsubscribed":false,"is_activeuser":0,"additionalemail":"seli@isotopia-mi.com","claimedemaildate":"2022-10-26 13:21:31.000000","initials":"ES","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sil  Weisemberg","email":"sderi@isotopia-global.com","phone":"","gender":"Female","userid":"7h7oI9xHQwQCtjG9AinoX4sogEBEflZLLN2lPpKLo7qSOZGb7HGri6","bounced":false,"claimed":1,"founder":0,"urlname":"sil-weisemberg","visible":1,"memberid":"Cn3yUt4KcQ2BE97ml8D4XBM58oYQrQTdz2tCqBIHLubTUcxxaiZVLN","position":"Marketing Communications Specialist","last_name":"Weisemberg","claimtoken":"bQpGs72cBcogD0dSqgsOWiJPTFC3NrV4GCzNJcGOJ3Azv0BggOkcQQ","first_name":"Sil ","picturekey":null,"claimeddate":"2023-09-08","linkedinurl":"https://www.linkedin.com/in/sildwe/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-07 14:09:11.000000","initials":"SW","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yossi Shohet","email":"yshohet@isotopia.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwMCY3IkJDA","bounced":false,"claimed":0,"founder":0,"urlname":"yossi-shohet","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAgPPDmQoM","position":"Plant engineer & Cyclotron PM","last_name":"Shohet","claimtoken":"nqXxZva8LHzla4PomBxxhkev0TUfRYMzttKQkLUcqoQGr1ftQEdpOb","first_name":"Yossi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yossi-shohet-644a512a/","unsubscribed":false,"is_activeuser":0,"additionalemail":"syossi@isotopia-mi.com","claimedemaildate":"2022-10-26 13:22:19.000000","initials":"YS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2019-11-20T00:00:00.000Z","crunchbaseid":"isotopia-molecular-imaging","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Paz Eliav","creator_email":"paze@cet.ac.il","createdate":"2016-04-10T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv4W9CAw","date":"Jul 2007","amount":"$3.75M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Metrontario","type":"Investor","amount":null,"hidden":false,"country":"Canada","fullurl":"/investor_page/metrontario","logokey":"$ztwuVkISPNJ6Qj528Rs9XsZ5njQtk3K2quPfYIklBATXgcqm2ESmnS","tagline":"Investment Organization","urlname":"/investor_page/metrontario","isisraeli":0,"investorid":"g3vKQYGhxirJn0HATi8u3NBGAI2U2J7kQojFmigPALFCoIoP7vDMku","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7UOSl4hSCKy6O9mljqUHREwJjsYh8ejZ2YLDgj9TeCIfjpVatgLR5a","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ztwuVkISPNJ6Qj528Rs9XsZ5njQtk3K2quPfYIklBATXgcqm2ESmnS","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":3750000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"2/2007","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Isotopia Molecular Imaging","logourl":"https://storage.googleapis.com/clean-finder-353810/$WZgb1ujn9CV6q9Ozlj4Qw1zb6TZ1G5qFv31XixSIvcaRAAnwjMqdYq","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$WZgb1ujn9CV6q9Ozlj4Qw1zb6TZ1G5qFv31XixSIvcaRAAnwjMqdYq","seoabout":"Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes diagnostic and therapeutic radioactive isotopes and ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Simulation & Imaging","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Medical Devices Industry","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Medical Equipment","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Juzz-kKDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Simulation & Imaging#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Medical Devices Industry#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Medical Devices Industry#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA>Medical Equipment#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Juzz-kKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Medical Devices Industry#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Medical Devices Industry#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA/Medical Equipment#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Juzz-kKDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Simulation & Imaging#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare"},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Medical Devices Industry","key":"0-0-2","path":"IndustryClassificationModel>Healthcare & Life Sciences>Medical Devices Industry","children":[{"title":"Medical Equipment","key":"0-0-2-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Medical Devices Industry>Medical Equipment"}]}]}],"coreTechnology":[{"title":"Simulation & Imaging","key":"0-0","path":"TechnologyClassificationModel>Simulation & Imaging"},{"title":"Biologicals","key":"0-1","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-1-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Simulation & Imaging","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Medical Devices Industry","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Medical Equipment","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Juzz-kKDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Simulation & Imaging","Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Life Sciences","Pharmaceuticals","Medical Devices Industry","Medical Equipment"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv4W9CAw","date":"Jul 2007","amount":"$3.75M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Metrontario","type":"Investor","amount":null,"hidden":false,"country":"Canada","fullurl":"/investor_page/metrontario","logokey":"$ztwuVkISPNJ6Qj528Rs9XsZ5njQtk3K2quPfYIklBATXgcqm2ESmnS","tagline":"Investment Organization","urlname":"/investor_page/metrontario","isisraeli":0,"investorid":"g3vKQYGhxirJn0HATi8u3NBGAI2U2J7kQojFmigPALFCoIoP7vDMku","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7UOSl4hSCKy6O9mljqUHREwJjsYh8ejZ2YLDgj9TeCIfjpVatgLR5a","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ztwuVkISPNJ6Qj528Rs9XsZ5njQtk3K2quPfYIklBATXgcqm2ESmnS","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":3750000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}